Table 1.
Basic information of patients.
| Variables | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
| Experimental group | Control group | P | Experimental group | Control group | P | |
| Total number of individuals | 122 | 141 | 62 | 62 | ||
| Age (years) | 65.31 ± 9.12 | 60.21 ± 8.21 | .001 | 62.11 ± 8.33 | 62.37 ± 7.69 | .549 |
| Gender | .336 | .105 | ||||
| Male | 62 | 80 | 29 | 38 | ||
| Female | 60 | 61 | 33 | 24 | ||
| Infection site | .022 | .283 | ||||
| Lung | 52 | 61 | 30 | 29 | ||
| Gastrointestinal tract | 10 | 12 | 8 | 10 | ||
| Biliary tract | 11 | 22 | 6 | 11 | ||
| Urinary system | 21 | 33 | 7 | 8 | ||
| Soft tissue | 28 | 13 | 11 | 4 | ||
| SOFA scores | 9.51 ± 2.34 | 9.34 ± 2.41 | .845 | 9.48 ± 2.11 | 9.34 ± 2.31 | .645 |
| APACHE II scores | 20.44 ± 2.16 | 23.36 ± 2.31 | .041 | 20.13 ± 2.33 | 19.98 ± 2.09 | .546 |
| Duration of sedation | 0.25 ± 0.02 | 0.26 ± 0.04 | .056 | 0.24 ± 0.02 | 0.24 ± 0.03 | .445 |
| Ventilator therapy | .902 | .472 | ||||
| Invasive | 51 | 60 | 30 | 34 | ||
| Noninvasive | 71 | 81 | 32 | 28 | ||
| Myocardial function index | ||||||
| MYO | 121.86 ± 9.56 | 126.33 ± 8.56 | .031 | 121.96 ± 11.56 | 121.88 ± 10.89 | .845 |
| HR | 121.36 ± 18.65 | 126.44 ± 17.26 | .001 | 116.12 ± 16.16 | 118.13 ± 15.77 | .547 |
| BNP | 811.31 ± 49.36 | 819.56 ± 49.99 | .065 | 810.21 ± 50.16 | 821.13 ± 55.76 | .515 |
| Hs-Tn I | 1.27 ± 0.69 | 1.25 ± 0.99 | .041 | 1.27 ± 0.54 | 1.26 ± 0.61 | .886 |
| CK-MB | 9.87 ± 2.21 | 9.89 ± 2.19 | .844 | 9.88 ± 2.17 | 9.86 ± 2.21 | .929 |
| LVEF | 41.96 ± 2.43 | 41.47 ± 2.01 | .544 | 40.21 ± 2.13 | 41.51 ± 2.03 | .187 |
| LVESD | 44.67 ± 4.31 | 46.21 ± 3.98 | .101 | 46.98 ± 3.30 | 48.01 ± 3.03 | .146 |
| LVEDD | 61.96 ± 3.21 | 63.03 ± 3.01 | .113 | 63.32 ± 3.09 | 62.98 ± 4.04 | .693 |
| PCT | 115.31 ± 15.36 | 116.21 ± 21.36 | .095 | 116.12 ± 16.16 | 118.13 ± 15.77 | .708 |
| IL-1β | 56.21 ± 20.36 | 54.36 ± 18.56 | .041 | 54.66 ± 19.63 | 55.46 ± 20.21 | .760 |
| IL-6 | 86.35 ± 18.61 | 87.66 ± 21.26 | .066 | 84.62 ± 21.44 | 85.33 ± 23.51 | .794 |
| IL-8 | 587.64 ± 121.46 | 572.36 ± 156.21 | .001 | 574.54 ± 132.16 | 571.46 ± 144.21 | .844 |
| TNFα | 196.12 ± 39.65 | 193.65 ± 45.36 | .041 | 199.66 ± 40.26 | 202.64 ± 42.31 | .692 |
| Medical history | ||||||
| Hypertension (yes) | 54 | 62 | .345 | 32 | 36 | .451 |
| Diabetes (yes) | 36 | 43 | .113 | 36 | 38 | .321 |
| Propensity score () | 0.21 ± 0.56 | .021 | 0.06 ± 0.31 | .061 | ||
APACHE II = Acute Physiology and Chronic Health Evaluation II, BNP = B-type natriuretic peptide, CK-MB = creatine kinase-MB, HR = heart rate, hs-TnI = high-sensitivity troponin I, IL-1β, IL-6, IL-8 = interleukins, LVEDD = left ventricular end-diastolic diameter, LVEF = left ventricular ejection fraction, LVESD = left ventricular end-systolic diameter, MYO = myocardial enzyme levels, PCT = procalcitonin, SOFA = Sequential Organ Failure Assessment, TNF-α = tumor necrosis factor-alpha.